Gracell - דינמיקת הכנסות משנה לשנה ב-12 החודשים האחרונים GRCL

Gracell Biotechnologies possesses significant pricing power thanks to its innovative CAR-T platform. Relative revenue growth over the last four quarters compared to last year demonstrates market dynamics, where the current metric equals -99.90. The business relies on external CRO/CMO contractors, while the asset's value is driven by scientific breakthroughs in oncology rather than general economic cycles.
Gracell (GRCL) - פילוחי מדדים ודוחות פיננסיים

Following the acquisition of Gracell Biotechnologies (GRCL) by a biopharmaceutical behemoth to scale CAR-T therapy, an analysis of year-over-year (TTM) sales growth allows for an assessment of how effectively resource integration is driving revenue. This indicator measures the percentage change in total income over the last twelve months relative to the same period last year, helping investors identify cash flow stability regardless of market volatility.